Perrigo Co. plc

Company Overview

Perrigo Company is a healthcare company focused on self-care products and prescription pharmaceuticals. It offers products for respiratory health, pain and sleep aids, healthy lifestyle, skincare and personal hygiene, digestive health, nutrition, prescription, and oral self-care. Its offers therapeutic formulations in topical, nasal sprays, ophthalmic, pre-filled syringes, injectables, and transdermal delivery systems. It reports its business in three reprtable segments: Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals.

Perrigo is one of the largest store brand OTC players in the U.S. The Company also commercializes and manufactures generic prescription products in the U.S. It distributes estradiol spray, developed by Acrux Ltd., by the brand name Evamist in the U.S., since 2009. Outside the U.S. the product is known as Lenzetto.

In March 2021, Perrigo Company Plc. entered in a definitive agreement with Altaris Capital Partners, LLC to sell to sell its generic RX Pharmaceuticals business for total consideration of $1.55 billion, including $1.5 billion in cash. The deal is expected to close by the end of the third quarter of 2021. The move is seen as a part of Perrigo long term strategy to establish itself as a pure-play consumer self-care company. The company classified its generic RX Pharmaceuticals business as discontinued operations starting in the first quarter of 2021.

Financial Highlights (FY 2025)

Company's Business Segments

• Consumer Self-Care Americas (CSCA) : This segment develops, manufactures, and markets its leading self-care consumer products in the U.S. and Canada.
• Consumer Self-Care International (CSCI) : This segment includes its consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia and store-brand products in the U.K. and parts of Europe and Asia.